 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY  Free Report)  Analysts at Wedbush raised their FY2023 earnings per share (EPS) estimates for shares of ARS Pharmaceuticals in a research note...

FY2023 Earnings Estimate for ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Issued By Wedbush

ARS Pharmaceuticals GAAP EPS of -$0.16...

ARS Pharmaceuticals GAAP EPS of -$0.16

Company is on track with ongoing repeat-dose study under allergen-induced allergic rhinitis conditions requested by U.S. FDA with topline data expected in Q1 2024 Resubmission of New Drug...

ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates

NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ: SPRY) concerning possible...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of ARS Pharmaceuticals, Inc. (SPRY)

Data to be Presented in Four Oral Presentations and Posters at the 2023 American College of Allergy, Asthma and Immunology Annual Scientific Meeting Supports neffy's potential to be a safe and...

ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy  (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of ARS Pharmaceuticals, Inc.: On September 19, 2023, ARS announced it received from the...

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of ARS Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit   (NASDAQ: SPRY)

NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Attention ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ: SPRY) shareholders: The Law Offices of Vincent Wong announce that an investigation has commenced...

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Investigate ARS Pharmaceuticals, Inc. (SPRY) for Potential Violations of Securities Laws

NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ: SPRY) concerning possible...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of ARS Pharmaceuticals, Inc.(SPRY)

Janney Montgomery Scott LLC purchased a new position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY  Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with...

39,969 Shares in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Acquired by Janney Montgomery Scott LLC

NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of ARS Pharmaceuticals, Inc.: On September 19, 2023, ARS announced it received from the...

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

Watchers	1,566
52-Wk Low	$2.55
52-Wk High	$9.65

Market Cap	$475.19M
Volume (M)	743,920.00
52-Wk High	$9.65
52-Wk Low	$2.55

SPRY ARS Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals